Skip to Main Content

Paper Details

A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBVâ¿¿+â¿¿lymphomas.
Leuk Lymphoma
14
2021
Author NameAffiliation
Borko JovanovicNorthwestern University
Andrew M EvensRutgers Cancer Institute of New Jersey
  • 1 - 2

Datasets

Release 1.2